Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)
An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male volunteer in the age between 19 and 55 years old.
- Body mass index (BMI) in the range of 18.5 to 27.0 kg/m2
- Understand the requirements of the study and voluntarily consent to participate in the study.
Exclusion Criteria:
- Previous history or present of clinically significant digestive , cardiovascular, respiratory, psychiatric, endocrine, hepatobiliary, renal disease.
- History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption.
- Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- Subjects whose clinical laboratory test values are outside the accepted normal range. Especially, ASTor ALT >1.5 times of the Upper Normal Limit or total bilirubin > 1.5 times of the Upper Normal Limit
- Positive test results for Hepatitis B antibodies, Hepatitis C virus antibody, and Syphilis regain test
- Participation in any clinical investigation within 3 months prior to study drug administration
- Subjects with whole blood donation within 60 days or component blood donation within 30days or blood transfusion within 30days prior to the first dosing.
- SBP ≥ 140 mmHg or< 115 mmHg, DBP ≥ 90 mmHg or < 70 mmHg
- Caffeine > 400mg/day
- Alcohol > 30g/day
- Cigarette > 10 cigarettes/day.
- Subjects who are judged unsuitable by investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Candesartan 16mg and Amlodipine 10mg
|
|
|
Experimental: HL068
HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
|
Candesartan 16mg and Amlodipine 10mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cmax
Time Frame: up to 72 hours
|
up to 72 hours
|
|
AUCt
Time Frame: up to 72 hours
|
up to 72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tmax
Time Frame: up to 72 hours
|
up to 72 hours
|
|
AUCinf
Time Frame: up to 72 hours
|
up to 72 hours
|
|
CL/F
Time Frame: up to 72 hours
|
up to 72 hours
|
|
t 1/2β
Time Frame: up to 72 hours
|
up to 72 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Young-Ran Yoon, M.D, Ph.D, KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL CLINICAL TRIAL CENTER
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension
- Calcium-Regulating Hormones and Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Calcium Channel Blockers
- Vasodilator Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Amlodipine
- Candesartan
- Candesartan cilexetil
Other Study ID Numbers
Other Study ID Numbers
- HL068
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.